AASLD Home
AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.
Cirrhosis Quality Collaborative
AASLD’s Cirrhosis Quality Collaborative (CQC) is a multi-site Learning Health Network that combines quality improvement and research to improve the care and treatment outcomes of patients with cirrhosis.
Quality Measures
AASLD develops quality measures to help its members measure or quantify healthcare processes and outcomes that are associated with the ability to provide high-quality health care.
NAFLD‐related hepatocellular carcinoma: The growing challenge
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison – 27 April 2022 – Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially. Genetic predisposition and clinical risk factors for NAFLD‐related HCC have been identified. Cirrhosis is a well‐known and major risk factor for NAFLD‐related HCC.
Letter to the editor: Hepatitis B virus genotype: A significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: The hepatitis B Alaska study
Aashish Kumar, Deepak Rajani, Satesh Kumar – 27 April 2022
Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit – 27 April 2022
Reply
Nupur Sharma, Manisha Yadav, Gaurav Tripathi, Babu Mathew, Vasundhra Bindal, Sanyam Falari, Viniyendra Pamecha, Jaswinder Singh Maras – 27 April 2022
The steatosis‐associated fibrosis estimator (SAFE) score: A tool to detect low‐risk NAFLD in primary care
Pimsiri Sripongpun, W. Ray Kim, Ajitha Mannalithara, Vivek Charu, Anna Vidovszky, Steven Asch, Manisha Desai, Sun H. Kim, Allison J. Kwong – 27 April 2022
Letter to the editor: For the core set of the bile lipidome and meta‐proteome signature, repeatability is the key
Shi‐Tao Jiang, Lei Zhang, Yi‐Yao Xu, Xin Lu – 27 April 2022
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
Rohini Sharma, Anjana Pillai, Thomas Urban Marron, Petros Fessas, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, David Szafron, Abdul Rafeh Naqash, Anuhya Gampa, Yinghong Wang, Uqba Khan, Mahvish Muzaffar, Chieh‐Ju Lee, Pei‐Chang Lee, Anushi Bulumulle, Sonal Paul, Dominic Bettinger, Hannah Hildebrand, Mohammed Yehia, Tiziana Pressiani, Ahmed Kaseb, Yi‐Hsiang Huang, Celina Ang, Masatoshi Kudo, Naoshi Nishida, Nicola Personeni, Lorenza Rimassa, David James Pinato – 27 April 2022 – The availability of immune checkpoint inhibitors (ICIs) for the management of advanced hepatocellular cancer (HC